Duchenne News Tags: ITF Therapeutics

On March 11, 2026, ITF Therapeutics shared a Community Letter outlining new data and analyses presented on DUVYZAT® (givinostat) at 2026 MDA Clinical and Scientific Conference. To view their Community...

On August 25, 2025, ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, announced publication of positive long-term safety and efficacy data for givinostat as a treatment for Duchenne muscular dystrophy...

On April 25, 2025, ITF Therapeutics announced that the Committee for Medicinal Products (CHMP) of the European Medicines Agency (EMA) recommended granting a conditional marketing authorization for DUVYZAT® (givinostat) for...

On March 17, 2025, ITF Therapeutics announced the presentation of seven abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held March 16-19, 2025, in Dallas, Texas....

DUVYZAT is a prescription medicine that is used for the treatment of Duchenne muscular dystrophy in people 6 years of age and older.